PulsePoint Launches HCP2DTC Influence, Bridging Provider Data with Direct‑to‑Consumer Ads, a new SaaS solution that fuses first‑party healthcare‑provider intelligence with programmatic DTC campaigns, marking the first agency‑led activation of the technology by CMI Media Group for a leading oncology brand.
PulsePoint, a Newark‑based ad‑tech firm that has built its reputation on data‑driven healthcare marketing, announced the commercial rollout of HCP2DTC Influence™ on July 23, 2026. The platform is designed to let pharmaceutical brands carry the granular insights they use to target physicians directly into the consumer‑facing side of their media mix. In practice, the system ingests a brand’s first‑party HCP data—specialties, prescribing patterns, geographic reach—and translates those signals into audience segments that can be bought programmatically across CTV, OTT, display and mobile inventory.
The debut activation, executed by CMI Media Group, applies the technology to an oncology therapeutic, linking the physician’s prescribing intent with patient‑level messaging that appears on the same devices patients use for health research. According to PulsePoint, the integration allows marketers to synchronize creative, frequency caps, and measurement windows across the HCP and DTC layers, eliminating the “data silo” that has traditionally hampered cross‑channel attribution.
Why the announcement matters goes beyond a single campaign. Gartner predicts that by 2025, more than 70 percent of ad spend will be programmatically executed, and a growing share of that spend will demand unified data models that span B2B and B2C audiences. HCP2DTC Influence directly addresses that need in the highly regulated healthcare sector, where first‑party data is both a competitive advantage and a compliance requirement. By surfacing provider‑level intent in real time, the platform promises more precise audience reach while reducing reliance on third‑party cookies that are rapidly disappearing under privacy legislation such as the EU’s GDPR and the U.S. CCPA.
From a technical standpoint, HCP2DTC Influence sits on PulsePoint’s existing CDP and DMP stack, leveraging AI‑powered identity resolution to match provider IDs to patient‑level identifiers in a privacy‑by‑design workflow. The solution also integrates with major demand‑side platforms—including The Trade Desk, MediaMath and Amazon DSP—allowing marketers to purchase inventory through a single interface while preserving the integrity of the provider‑derived segment.
The move positions PulsePoint against established players like Salesforce’s Advertising Studio and Adobe Advertising Cloud, which offer generic B2B‑to‑B2C bridging but lack the deep, specialty‑specific provider taxonomy that PulsePoint has cultivated through years of healthcare partnerships. CMI Media Group’s early adoption underscores a broader industry trend: agencies are seeking turnkey solutions that can translate their client’s clinical expertise into measurable consumer outcomes without building custom data pipelines.
For enterprise marketing teams, the practical implications are immediate. First‑party HCP data can now feed directly into media plans, enabling real‑time optimization of spend based on both prescriber behavior and patient engagement metrics. The unified measurement model also simplifies attribution, allowing brands to credit a single conversion path that spans physician recommendation, patient awareness, and final purchase. In an environment where ROI scrutiny is intensifying, the ability to close the loop between provider influence and consumer action could become a decisive factor in media budgeting decisions.
Nevertheless, adoption will hinge on rigorous data governance. The platform must navigate FDA regulations around promotional content, ensure HIPAA‑compliant handling of any patient‑level signals, and maintain transparent consent mechanisms. PulsePoint reports that its compliance engine is built on a modular policy engine that can be customized per market, but third‑party audits will likely be required before broader rollout.
Looking ahead, the HCP2DTC Influence model could serve as a blueprint for other regulated verticals—such as financial services and automotive—where B2B relationships drive consumer purchasing decisions. If the oncology pilot delivers the promised lift in both prescriber engagement and patient acquisition, the technology may accelerate the convergence of programmatic advertising and domain‑specific data ecosystems across the ad‑tech landscape.
What the platform does
HCP2DTC Influence converts first‑party healthcare‑provider data into programmatically purchasable audience segments, enabling synchronized HCP and DTC campaigns across CTV, OTT, display and mobile.
Why it matters to marketers
The solution tackles the industry‑wide challenge of siloed data, offering a single source of truth for both physician‑targeted and consumer‑targeted media, which improves reach efficiency and attribution clarity.
Competitive context
Unlike generic B2B‑to‑B2C tools from Salesforce or Adobe, PulsePoint’s offering leverages a proprietary provider taxonomy and AI‑driven identity resolution, giving it a niche advantage in the pharma ad‑tech space.
Implications for enterprise teams
Marketing departments can now align spend, creative, and measurement across the full patient journey, reducing manual data stitching and accelerating optimization cycles.
Market Landscape
The ad‑tech market is at a crossroads where privacy regulations, the decline of third‑party cookies, and the rise of first‑party data are reshaping buying strategies. According to a recent Forrester study, 62 percent of marketers plan to double their investment in CDP‑driven activation by 2027. In parallel, the healthcare advertising segment is projected by Statista to exceed $15 billion in 2026, driven by an aging population and increasing drug launches. PulsePoint’s HCP2DTC Influence taps into both trends, offering a compliant, data‑rich bridge that aligns with the broader shift toward unified, AI‑enabled media buying.
Top Insights
- HCP2DTC Influence merges provider‑level intelligence with programmatic DTC buying, eliminating data silos that have long hampered healthcare campaigns.
- The platform’s AI‑driven identity resolution enables cross‑device targeting while staying compliant with GDPR, CCPA and HIPAA.
- Early adoption by CMI Media Group signals agency appetite for turnkey solutions that translate clinical expertise into measurable consumer outcomes.
- Compared with generic B2B‑to‑B2C tools, PulsePoint’s specialty‑specific taxonomy offers a competitive edge in pharma advertising.
- Success in the oncology pilot could catalyze similar provider‑to‑consumer models in other regulated industries, accelerating the convergence of programmatic and domain‑specific data.
Get in touch with our Adtech experts
